The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...

Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the ...

In a new study, researchers have determined that a protein called NF-kB c-Rel can intensify the symptoms of psoriasis when activated by signals from the body's immune system. Understanding how 'c-Rel' ...

Finding offers potential new target for treatmentPsoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide ...

CLEVELAND—Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

1 Department of Clinical Immunology, University Hospital, Groningen, The Netherlands 2 Department of Rheumatology, University Hospital, Groningen, The Netherlands 3 Department of Pathology ... int.azg ...

Objective Metabolic reprogramming plays a critical role in modulating the innate and adaptive immune response, but its role in cutaneous autoimmune diseases, such as cutaneous lupus erythematosus ...